Difficulty: Medium
Average Score: 77%
Practice
A 75-year-old man with a 40-pack-year history of smoking and known chronic obstructive pulmonary disease complains of intermittent cough. Physical examination reveals wheezing, which is suggestive of bronchospasm. Which of the following is the most appropriate treatment for this patient?
Correct answer
A
Rationale
In this scenario, the most appropriate treatment for a 75-year-old man with a history of smoking and chronic obstructive pulmonary disease experiencing bronchospasm is option A) Ipratropium aerosol.
Rationale:
1. Ipratropium is an anticholinergic bronchodilator that helps relax the airways, making it easier to breathe. This is particularly beneficial for bronchospasm, a common issue in COPD patients.
2. Mecamylamine is a ganglionic blocker and not typically used for bronchospasm.
3. Nicotine replacement therapy is aimed at smoking cessation and not for acute bronchospasm treatment.
4. Oxygen therapy is important in managing respiratory distress but does not directly address bronchospasm.
Educational Context:
Understanding the appropriate pharmacological interventions for respiratory conditions like bronchospasm in COPD patients is crucial for healthcare providers. Ipratropium's mechanism of action, efficacy, and side effects should be well-understood to ensure optimal patient care and outcomes. This case highlights the importance of tailored treatment based on individual patient factors like age, smoking history, and underlying conditions.
Rationale:
1. Ipratropium is an anticholinergic bronchodilator that helps relax the airways, making it easier to breathe. This is particularly beneficial for bronchospasm, a common issue in COPD patients.
2. Mecamylamine is a ganglionic blocker and not typically used for bronchospasm.
3. Nicotine replacement therapy is aimed at smoking cessation and not for acute bronchospasm treatment.
4. Oxygen therapy is important in managing respiratory distress but does not directly address bronchospasm.
Educational Context:
Understanding the appropriate pharmacological interventions for respiratory conditions like bronchospasm in COPD patients is crucial for healthcare providers. Ipratropium's mechanism of action, efficacy, and side effects should be well-understood to ensure optimal patient care and outcomes. This case highlights the importance of tailored treatment based on individual patient factors like age, smoking history, and underlying conditions.